Saku Biosciences

Scaling Biomanufacturing
Los Angeles

About Saku Biosciences

Saku’s core objective is to commercialize manufacturing-grade, producer host cell products for use by CDMOs and biotechnology companies.

Saku’s host cells are designed to improve three core levers of biological manufacturing economics:

Productivity-
Higher titers reduce required reactor volume, capital intensity, batch counts, and operating costs. Improvements at the cell level compound dramatically at commercial scale, improving unit economics and throughput.

Feedstock Flexibility and Supply Chain Resilience-
Most production hosts are optimized around narrow, expensive feedstocks. This constrains geographic flexibility, increases exposure to commodity price volatility, and limits the ability to localize production. Host cells that can efficiently utilize alternative or regionally available feedstocks unlock lower input costs and more resilient supply chains.

Downstream Processing Complexity-
Cell physiology directly affects impurity profiles, secretion efficiency, and byproduct formation. Poorly optimized hosts increase downstream burden, which often represents a majority of total cost of goods. Improvements at the host cell level can materially simplify purification and reduce downstream capital and operating costs.

Because host cells sit at the foundation of the manufacturing stack, improvements at this level create significant economic impact.

Team

Problem statement

Most existing suppliers provide research-grade host cells intended for early development. These host cells typically require reengineering before they are suitable for industrial production. Host cell reengineering takes at least 10 years to achieve commercial readiness. Given this timeline and attendant capital constraints, most companies cannot begin to scale for 2 or 3 years and must accept suboptimal host performance to for commercial manufacturing.

This decision can translate into tens of millions of dollars per year in lost value for commercial-scale products. Once manufacturing is established, switching host cells becomes prohibitively expensive due to revalidation, regulatory, and operational constraints.

Traction information

1. Completed CRADA with DOE, Lawrence Berkely National Lab & ABPDU showed 37% and 41% titer improvement.
2. Multiple CDMO Partnerships; announcing partnership between Novozymes, RTI, GCB and NCBiotech
3. Multiple signed customer contracts

Updates

Profile created.
Added about 3 hours ago
Pitch is a Capital Factory product. © Capital Factory 2024. Privacy policy.